The global market for Mirabegron Sustained-release Tablets was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Mirabegron sustained-release tablets are designed to provide a controlled release of the medication over an extended period, which helps maintain stable levels of mirabegron in the bloodstream.This formulation is used to treat overactive bladder (OAB) symptoms, including frequent urination, urgency, and urinary incontinence.

North American market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Mirabegron Sustained-release Tablets include Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, Zhejiang Huayi Pharmaceutical, China Resources Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, CSPC Pharmaceutical, Qilu Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Mirabegron Sustained-release Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mirabegron Sustained-release Tablets.

The Mirabegron Sustained-release Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mirabegron Sustained-release Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Mirabegron Sustained-release Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Mirabegron Sustained-release Tablets Market Report

Report Metric	Details
Report Name	Mirabegron Sustained-release Tablets Market
Segment by Type	25mg per Tablet 50mg per Tablet
Segment by Application	Hospital and Clinic Pharmacy Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, Zhejiang Huayi Pharmaceutical, China Resources Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, CSPC Pharmaceutical, Qilu Pharmaceutical, Jiangsu Huayang Pharmaceutical, Sichuan Gowell Pharmaceutical, Shenzhen Main Luck Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Mirabegron Sustained-release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Mirabegron Sustained-release Tablets Market report?

Ans: The main players in the Mirabegron Sustained-release Tablets Market are Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, Zhejiang Huayi Pharmaceutical, China Resources Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, CSPC Pharmaceutical, Qilu Pharmaceutical, Jiangsu Huayang Pharmaceutical, Sichuan Gowell Pharmaceutical, Shenzhen Main Luck Pharmaceuticals

What are the Application segmentation covered in the Mirabegron Sustained-release Tablets Market report?

Ans: The Applications covered in the Mirabegron Sustained-release Tablets Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the Mirabegron Sustained-release Tablets Market report?

Ans: The Types covered in the Mirabegron Sustained-release Tablets Market report are 25mg per Tablet, 50mg per Tablet

1 Mirabegron Sustained-release Tablets Market Overview

1.1 Product Definition

1.2 Mirabegron Sustained-release Tablets by Type

1.2.1 Global Mirabegron Sustained-release Tablets Market Value Comparison by Type (2024 VS 2031)

1.2.2 25mg per Tablet

1.2.3 50mg per Tablet

1.3 Mirabegron Sustained-release Tablets by Application

1.3.1 Global Mirabegron Sustained-release Tablets Market Value by Application (2024 VS 2031)

1.3.2 Hospital and Clinic

1.3.3 Pharmacy

1.3.4 Other

1.4 Global Mirabegron Sustained-release Tablets Market Size Estimates and Forecasts

1.4.1 Global Mirabegron Sustained-release Tablets Revenue 2020-2031

1.4.2 Global Mirabegron Sustained-release Tablets Sales 2020-2031

1.4.3 Global Mirabegron Sustained-release Tablets Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Mirabegron Sustained-release Tablets Market Competition by Manufacturers

2.1 Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers (2020-2025)

2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Mirabegron Sustained-release Tablets Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Mirabegron Sustained-release Tablets, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Mirabegron Sustained-release Tablets, Product Type & Application

2.7 Global Key Manufacturers of Mirabegron Sustained-release Tablets, Date of Enter into This Industry

2.8 Global Mirabegron Sustained-release Tablets Market Competitive Situation and Trends

2.8.1 Global Mirabegron Sustained-release Tablets Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Mirabegron Sustained-release Tablets Players Market Share by Revenue

2.8.3 Global Mirabegron Sustained-release Tablets Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Mirabegron Sustained-release Tablets Market Scenario by Region

3.1 Global Mirabegron Sustained-release Tablets Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2020-2031

3.2.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2020-2025

3.2.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2026-2031

3.3 Global Mirabegron Sustained-release Tablets Revenue by Region: 2020-2031

3.3.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2020-2025

3.3.2 Global Mirabegron Sustained-release Tablets Revenue by Region: 2026-2031

3.4 North America Mirabegron Sustained-release Tablets Market Facts & Figures by Country

3.4.1 North America Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Mirabegron Sustained-release Tablets Sales by Country (2020-2031)

3.4.3 North America Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Mirabegron Sustained-release Tablets Market Facts & Figures by Country

3.5.1 Europe Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2020-2031)

3.5.3 Europe Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Mirabegron Sustained-release Tablets Market Facts & Figures by Region

3.6.1 Asia Pacific Mirabegron Sustained-release Tablets Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Mirabegron Sustained-release Tablets Sales by Region (2020-2031)

3.6.3 Asia Pacific Mirabegron Sustained-release Tablets Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Mirabegron Sustained-release Tablets Market Facts & Figures by Country

3.7.1 Latin America Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Mirabegron Sustained-release Tablets Sales by Country (2020-2031)

3.7.3 Latin America Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Mirabegron Sustained-release Tablets Market Facts & Figures by Country

3.8.1 Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2020-2031)

3.8.3 Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2031)

4.1.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2025)

4.1.2 Global Mirabegron Sustained-release Tablets Sales by Type (2026-2031)

4.1.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2020-2031)

4.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2020-2031)

4.2.1 Global Mirabegron Sustained-release Tablets Revenue by Type (2020-2025)

4.2.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2026-2031)

4.2.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2020-2031)

4.3 Global Mirabegron Sustained-release Tablets Price by Type (2020-2031)

5 Segment by Application

5.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2031)

5.1.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2025)

5.1.2 Global Mirabegron Sustained-release Tablets Sales by Application (2026-2031)

5.1.3 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2020-2031)

5.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2020-2031)

5.2.1 Global Mirabegron Sustained-release Tablets Revenue by Application (2020-2025)

5.2.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2026-2031)

5.2.3 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2020-2031)

5.3 Global Mirabegron Sustained-release Tablets Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Astellas Pharma

6.1.1 Astellas Pharma Company Information

6.1.2 Astellas Pharma Description and Business Overview

6.1.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio

6.1.5 Astellas Pharma Recent Developments/Updates

6.2 Zydus Lifesciences

6.2.1 Zydus Lifesciences Company Information

6.2.2 Zydus Lifesciences Description and Business Overview

6.2.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio

6.2.5 Zydus Lifesciences Recent Developments/Updates

6.3 Lupin Pharmaceuticals

6.3.1 Lupin Pharmaceuticals Company Information

6.3.2 Lupin Pharmaceuticals Description and Business Overview

6.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio

6.3.5 Lupin Pharmaceuticals Recent Developments/Updates

6.4 Alkem Laboratories

6.4.1 Alkem Laboratories Company Information

6.4.2 Alkem Laboratories Description and Business Overview

6.4.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio

6.4.5 Alkem Laboratories Recent Developments/Updates

6.5 Chia Tai Tianqing Pharmaceutical

6.5.1 Chia Tai Tianqing Pharmaceutical Company Information

6.5.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview

6.5.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.5.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

6.6 Zhejiang Huayi Pharmaceutical

6.6.1 Zhejiang Huayi Pharmaceutical Company Information

6.6.2 Zhejiang Huayi Pharmaceutical Description and Business Overview

6.6.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.6.5 Zhejiang Huayi Pharmaceutical Recent Developments/Updates

6.7 China Resources Pharmaceutical

6.7.1 China Resources Pharmaceutical Company Information

6.7.2 China Resources Pharmaceutical Description and Business Overview

6.7.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.7.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.7.5 China Resources Pharmaceutical Recent Developments/Updates

6.8 Jiangxi Shanxiang Pharmaceutical

6.8.1 Jiangxi Shanxiang Pharmaceutical Company Information

6.8.2 Jiangxi Shanxiang Pharmaceutical Description and Business Overview

6.8.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.8.5 Jiangxi Shanxiang Pharmaceutical Recent Developments/Updates

6.9 CSPC Pharmaceutical

6.9.1 CSPC Pharmaceutical Company Information

6.9.2 CSPC Pharmaceutical Description and Business Overview

6.9.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.9.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.9.5 CSPC Pharmaceutical Recent Developments/Updates

6.10 Qilu Pharmaceutical

6.10.1 Qilu Pharmaceutical Company Information

6.10.2 Qilu Pharmaceutical Description and Business Overview

6.10.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.10.5 Qilu Pharmaceutical Recent Developments/Updates

6.11 Jiangsu Huayang Pharmaceutical

6.11.1 Jiangsu Huayang Pharmaceutical Company Information

6.11.2 Jiangsu Huayang Pharmaceutical Description and Business Overview

6.11.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.11.5 Jiangsu Huayang Pharmaceutical Recent Developments/Updates

6.12 Sichuan Gowell Pharmaceutical

6.12.1 Sichuan Gowell Pharmaceutical Company Information

6.12.2 Sichuan Gowell Pharmaceutical Description and Business Overview

6.12.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio

6.12.5 Sichuan Gowell Pharmaceutical Recent Developments/Updates

6.13 Shenzhen Main Luck Pharmaceuticals

6.13.1 Shenzhen Main Luck Pharmaceuticals Company Information

6.13.2 Shenzhen Main Luck Pharmaceuticals Description and Business Overview

6.13.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio

6.13.5 Shenzhen Main Luck Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Mirabegron Sustained-release Tablets Industry Chain Analysis

7.2 Mirabegron Sustained-release Tablets Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Mirabegron Sustained-release Tablets Production Mode & Process Analysis

7.4 Mirabegron Sustained-release Tablets Sales and Marketing

7.4.1 Mirabegron Sustained-release Tablets Sales Channels

7.4.2 Mirabegron Sustained-release Tablets Distributors

7.5 Mirabegron Sustained-release Tablets Customer Analysis

8 Mirabegron Sustained-release Tablets Market Dynamics

8.1 Mirabegron Sustained-release Tablets Industry Trends

8.2 Mirabegron Sustained-release Tablets Market Drivers

8.3 Mirabegron Sustained-release Tablets Market Challenges

8.4 Mirabegron Sustained-release Tablets Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astellas Pharma

Zydus Lifesciences

Lupin Pharmaceuticals

Alkem Laboratories

Chia Tai-Tianqing Pharmaceutical

Zhejiang Huayi Pharmaceutical

China Resources Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

CSPC Pharmaceutical

Qilu Pharmaceutical

Jiangsu Huayang Pharmaceutical

Sichuan Gowell Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

List of Tables

Table 1. Global Mirabegron Sustained-release Tablets Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Mirabegron Sustained-release Tablets Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Mirabegron Sustained-release Tablets Market Competitive Situation by Manufacturers in 2024

Table 4. Global Mirabegron Sustained-release Tablets Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Mirabegron Sustained-release Tablets Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Mirabegron Sustained-release Tablets Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Mirabegron Sustained-release Tablets Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Mirabegron Sustained-release Tablets Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Mirabegron Sustained-release Tablets, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Mirabegron Sustained-release Tablets, Product Type & Application

Table 12. Global Key Manufacturers of Mirabegron Sustained-release Tablets, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Mirabegron Sustained-release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mirabegron Sustained-release Tablets as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Mirabegron Sustained-release Tablets Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Mirabegron Sustained-release Tablets Sales by Region (2020-2025) & (K Units)

Table 18. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2020-2025)

Table 19. Global Mirabegron Sustained-release Tablets Sales by Region (2026-2031) & (K Units)

Table 20. Global Mirabegron Sustained-release Tablets Sales Market Share by Region (2026-2031)

Table 21. Global Mirabegron Sustained-release Tablets Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2020-2025)

Table 23. Global Mirabegron Sustained-release Tablets Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Mirabegron Sustained-release Tablets Revenue Market Share by Region (2026-2031)

Table 25. North America Mirabegron Sustained-release Tablets Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Mirabegron Sustained-release Tablets Sales by Country (2020-2025) & (K Units)

Table 27. North America Mirabegron Sustained-release Tablets Sales by Country (2026-2031) & (K Units)

Table 28. North America Mirabegron Sustained-release Tablets Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Mirabegron Sustained-release Tablets Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Mirabegron Sustained-release Tablets Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Mirabegron Sustained-release Tablets Sales by Country (2020-2025) & (K Units)

Table 32. Europe Mirabegron Sustained-release Tablets Sales by Country (2026-2031) & (K Units)

Table 33. Europe Mirabegron Sustained-release Tablets Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Mirabegron Sustained-release Tablets Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Mirabegron Sustained-release Tablets Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Mirabegron Sustained-release Tablets Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Mirabegron Sustained-release Tablets Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Mirabegron Sustained-release Tablets Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Mirabegron Sustained-release Tablets Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Mirabegron Sustained-release Tablets Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Mirabegron Sustained-release Tablets Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Mirabegron Sustained-release Tablets Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Mirabegron Sustained-release Tablets Sales (K Units) by Type (2020-2025)

Table 51. Global Mirabegron Sustained-release Tablets Sales (K Units) by Type (2026-2031)

Table 52. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2020-2025)

Table 53. Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2026-2031)

Table 54. Global Mirabegron Sustained-release Tablets Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Mirabegron Sustained-release Tablets Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2020-2025)

Table 57. Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2026-2031)

Table 58. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Type (2020-2025)

Table 59. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Type (2026-2031)

Table 60. Global Mirabegron Sustained-release Tablets Sales (K Units) by Application (2020-2025)

Table 61. Global Mirabegron Sustained-release Tablets Sales (K Units) by Application (2026-2031)

Table 62. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2020-2025)

Table 63. Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2026-2031)

Table 64. Global Mirabegron Sustained-release Tablets Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Mirabegron Sustained-release Tablets Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2020-2025)

Table 67. Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2026-2031)

Table 68. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Application (2020-2025)

Table 69. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Application (2026-2031)

Table 70. Astellas Pharma Company Information

Table 71. Astellas Pharma Description and Business Overview

Table 72. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Astellas Pharma Mirabegron Sustained-release Tablets Product

Table 74. Astellas Pharma Recent Developments/Updates

Table 75. Zydus Lifesciences Company Information

Table 76. Zydus Lifesciences Description and Business Overview

Table 77. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Zydus Lifesciences Mirabegron Sustained-release Tablets Product

Table 79. Zydus Lifesciences Recent Developments/Updates

Table 80. Lupin Pharmaceuticals Company Information

Table 81. Lupin Pharmaceuticals Description and Business Overview

Table 82. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product

Table 84. Lupin Pharmaceuticals Recent Developments/Updates

Table 85. Alkem Laboratories Company Information

Table 86. Alkem Laboratories Description and Business Overview

Table 87. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Alkem Laboratories Mirabegron Sustained-release Tablets Product

Table 89. Alkem Laboratories Recent Developments/Updates

Table 90. Chia Tai Tianqing Pharmaceutical Company Information

Table 91. Chia Tai Tianqing Pharmaceutical Description and Business Overview

Table 92. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 94. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 95. Zhejiang Huayi Pharmaceutical Company Information

Table 96. Zhejiang Huayi Pharmaceutical Description and Business Overview

Table 97. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 99. Zhejiang Huayi Pharmaceutical Recent Developments/Updates

Table 100. China Resources Pharmaceutical Company Information

Table 101. China Resources Pharmaceutical Description and Business Overview

Table 102. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 104. China Resources Pharmaceutical Recent Developments/Updates

Table 105. Jiangxi Shanxiang Pharmaceutical Company Information

Table 106. Jiangxi Shanxiang Pharmaceutical Description and Business Overview

Table 107. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 109. Jiangxi Shanxiang Pharmaceutical Recent Developments/Updates

Table 110. CSPC Pharmaceutical Company Information

Table 111. CSPC Pharmaceutical Description and Business Overview

Table 112. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 114. CSPC Pharmaceutical Recent Developments/Updates

Table 115. Qilu Pharmaceutical Company Information

Table 116. Qilu Pharmaceutical Description and Business Overview

Table 117. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 119. Qilu Pharmaceutical Recent Developments/Updates

Table 120. Jiangsu Huayang Pharmaceutical Company Information

Table 121. Jiangsu Huayang Pharmaceutical Description and Business Overview

Table 122. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 124. Jiangsu Huayang Pharmaceutical Recent Developments/Updates

Table 125. Sichuan Gowell Pharmaceutical Company Information

Table 126. Sichuan Gowell Pharmaceutical Description and Business Overview

Table 127. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product

Table 129. Sichuan Gowell Pharmaceutical Recent Developments/Updates

Table 130. Shenzhen Main Luck Pharmaceuticals Company Information

Table 131. Shenzhen Main Luck Pharmaceuticals Description and Business Overview

Table 132. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product

Table 134. Shenzhen Main Luck Pharmaceuticals Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Mirabegron Sustained-release Tablets Distributors List

Table 138. Mirabegron Sustained-release Tablets Customers List

Table 139. Mirabegron Sustained-release Tablets Market Trends

Table 140. Mirabegron Sustained-release Tablets Market Drivers

Table 141. Mirabegron Sustained-release Tablets Market Challenges

Table 142. Mirabegron Sustained-release Tablets Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Mirabegron Sustained-release Tablets

Figure 2. Global Mirabegron Sustained-release Tablets Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Mirabegron Sustained-release Tablets Market Share by Type: 2024 & 2031

Figure 4. 25mg per Tablet Product Picture

Figure 5. 50mg per Tablet Product Picture

Figure 6. Global Mirabegron Sustained-release Tablets Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Mirabegron Sustained-release Tablets Market Share by Application: 2024 & 2031

Figure 8. Hospital and Clinic

Figure 9. Pharmacy

Figure 10. Other

Figure 11. Global Mirabegron Sustained-release Tablets Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Mirabegron Sustained-release Tablets Market Size (2020-2031) & (US$ Million)

Figure 13. Global Mirabegron Sustained-release Tablets Sales (2020-2031) & (K Units)

Figure 14. Global Mirabegron Sustained-release Tablets Average Price (US$/Unit) & (2020-2031)

Figure 15. Mirabegron Sustained-release Tablets Report Years Considered

Figure 16. Mirabegron Sustained-release Tablets Sales Share by Manufacturers in 2024

Figure 17. Global Mirabegron Sustained-release Tablets Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Mirabegron Sustained-release Tablets Players: Market Share by Revenue in Mirabegron Sustained-release Tablets in 2024

Figure 19. Mirabegron Sustained-release Tablets Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Mirabegron Sustained-release Tablets Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Mirabegron Sustained-release Tablets Sales Market Share by Country (2020-2031)

Figure 22. North America Mirabegron Sustained-release Tablets Revenue Market Share by Country (2020-2031)

Figure 23. United States Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Mirabegron Sustained-release Tablets Sales Market Share by Country (2020-2031)

Figure 26. Europe Mirabegron Sustained-release Tablets Revenue Market Share by Country (2020-2031)

Figure 27. Germany Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Mirabegron Sustained-release Tablets Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Mirabegron Sustained-release Tablets Revenue Market Share by Region (2020-2031)

Figure 34. China Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. China Taiwan Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Latin America Mirabegron Sustained-release Tablets Sales Market Share by Country (2020-2031)

Figure 42. Latin America Mirabegron Sustained-release Tablets Revenue Market Share by Country (2020-2031)

Figure 43. Mexico Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Brazil Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Argentina Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Colombia Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa Mirabegron Sustained-release Tablets Revenue Market Share by Country (2020-2031)

Figure 49. Turkey Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. UAE Mirabegron Sustained-release Tablets Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Global Sales Market Share of Mirabegron Sustained-release Tablets by Type (2020-2031)

Figure 53. Global Revenue Market Share of Mirabegron Sustained-release Tablets by Type (2020-2031)

Figure 54. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Type (2020-2031)

Figure 55. Global Sales Market Share of Mirabegron Sustained-release Tablets by Application (2020-2031)

Figure 56. Global Revenue Market Share of Mirabegron Sustained-release Tablets by Application (2020-2031)

Figure 57. Global Mirabegron Sustained-release Tablets Price (US$/Unit) by Application (2020-2031)

Figure 58. Mirabegron Sustained-release Tablets Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions